Drug Trial Radar · NCT07750925
Examining Lithium's Mechanism in Bipolar Disorder
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
45
Planned (sponsor's estimate)
Start
Sep 21, 2026
Primary completion
Apr 30, 2028
Study completion Apr 30, 2029
Sponsor
- Lead sponsor
- Northumbria UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Newcastle University; Northumberland, Tyne and Wear NHS Foundation Trust
- First posted
- Aug 6, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of the current study is to examine the acute effect of lithium on the visual and non-visual responses to light in a sample of healthy participants. Our experiments will investigate the effects of lithium on light sensitivity at the level of the retina as well as central visual and non-visual pathways. Our primary hypothesis is that the administration of lithium to healthy volunteers will reduce the magnitude of a range of non-visual responses to light including melatonin suppression, alertness, performance, mood and electrophysiology in a manner that is dependent of the amount of lithium in the brain. To better understand the postulated effects of lithium on light sensitivity and to examine its relationship at the level of the retina, we will assess the visual and non-visual responses to light, as well as the distribution of lithium in the brain using a non-invasive imaging technique. In addition to that, we also aim to examine the impact of both lithium and light on a molecular level through whole blood transcriptome sequencing.
Conditions
- Healthy
- Bipolar
Interventions
Lithium carbonate (Priadel)Drug
Oral lithium carbonate 600 mg daily for 7 days prior to the second laboratory assessment (and for both days while in the laboratory)
Controlled light exposureOther
Participants undergo 90-minute dim light (\<1 lux) and light exposure (100-850 lux) conditions during laboratory assessments to evaluate visual and non-visual responses to light.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Plasma melatonin change in response to light stimulationTime frame: Measured during the 90-minute light exposure session after 7 days of lithium treatment and after 7 days in the no-lithium condition (days 9-11 and 19-21).
- Brain lithium signal intensity measured by 7Li-MRITime frame: Measured once following 9 days of lithium carbonate administration (Day 21)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Northumbria University
Newcastle upon Tyne, Tyne & Wear, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.